Monogram Technologies to Host First Quarter 2025 Results Conference Call on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time
Monogram Technologies (NASDAQ:MGRM), an AI-driven robotics company focused on orthopedic surgery, has scheduled its Q1 2025 earnings conference call for May 14, 2025, at 4:30 p.m. Eastern Time. CEO Ben Sexson and CFO Noel Knape will host the webcast, which will cover financial results for the quarter ended March 31, 2025, regulatory updates, and key milestones.
The call will include discussions on their recent FDA 510(k) Clearance for the Monogram mBôs TKA System and approval to initiate clinical trials in India. A detailed press release will be issued before the call, and a presentation will be available through the company's investor relations website.
Monogram Technologies (NASDAQ:MGRM), un'azienda di robotica basata sull'intelligenza artificiale specializzata in chirurgia ortopedica, ha programmato la conferenza telefonica sui risultati del primo trimestre 2025 per il 14 maggio 2025 alle 16:30 ora orientale. Il CEO Ben Sexson e il CFO Noel Knape condurranno la webcast, che tratterà i risultati finanziari del trimestre terminato il 31 marzo 2025, aggiornamenti normativi e traguardi importanti.
Durante la chiamata si discuterà della recente approvazione FDA 510(k) per il sistema Monogram mBôs TKA e del via libera per l'avvio di studi clinici in India. Prima della chiamata sarà pubblicato un comunicato stampa dettagliato e sarà disponibile una presentazione sul sito web delle relazioni con gli investitori dell'azienda.
Monogram Technologies (NASDAQ:MGRM), una empresa de robótica impulsada por IA enfocada en cirugía ortopédica, ha programado su conferencia telefónica de resultados del primer trimestre de 2025 para el 14 de mayo de 2025 a las 4:30 p.m. hora del Este. El CEO Ben Sexson y el CFO Noel Knape presentarán la transmisión web, que cubrirá los resultados financieros del trimestre finalizado el 31 de marzo de 2025, actualizaciones regulatorias y hitos clave.
La llamada incluirá discusiones sobre la reciente aprobación FDA 510(k) para el sistema Monogram mBôs TKA y la autorización para iniciar ensayos clínicos en India. Se emitirá un comunicado de prensa detallado antes de la llamada, y una presentación estará disponible en el sitio web de relaciones con inversionistas de la empresa.
Monogram Technologies (NASDAQ:MGRM)은 인공지능 기반 정형외과 수술 로봇 회사로, 2025년 1분기 실적 컨퍼런스 콜을 2025년 5월 14일 동부시간 오후 4시 30분에 예정했습니다. CEO 벤 섹슨과 CFO 노엘 크네이프가 웹캐스트를 진행하며, 2025년 3월 31일 종료된 분기의 재무 결과, 규제 업데이트 및 주요 이정표를 다룰 예정입니다.
이번 콜에서는 최근 Monogram mBôs TKA 시스템에 대한 FDA 510(k) 승인과 인도에서 임상 시험 개시 승인에 대해 논의할 예정입니다. 콜 전에 상세 보도자료가 배포되며, 회사 투자자 관계 웹사이트를 통해 프레젠테이션도 제공됩니다.
Monogram Technologies (NASDAQ:MGRM), une entreprise de robotique pilotée par l'IA spécialisée en chirurgie orthopédique, a programmé sa conférence téléphonique sur les résultats du premier trimestre 2025 pour le 14 mai 2025 à 16h30 heure de l'Est. Le PDG Ben Sexson et le directeur financier Noel Knape animeront le webcast, qui couvrira les résultats financiers du trimestre clos le 31 mars 2025, les mises à jour réglementaires et les étapes clés.
La conférence inclura des discussions sur la récente validation FDA 510(k) du système Monogram mBôs TKA et l'autorisation de lancer des essais cliniques en Inde. Un communiqué de presse détaillé sera publié avant l'appel, et une présentation sera disponible sur le site des relations investisseurs de l'entreprise.
Monogram Technologies (NASDAQ:MGRM), ein KI-gesteuertes Robotikunternehmen mit Fokus auf orthopädische Chirurgie, hat seine Telefonkonferenz zu den Ergebnissen des ersten Quartals 2025 für den 14. Mai 2025 um 16:30 Uhr Eastern Time angesetzt. CEO Ben Sexson und CFO Noel Knape werden das Webcast moderieren, das die Finanzergebnisse für das am 31. März 2025 endende Quartal, regulatorische Updates und wichtige Meilensteine behandelt.
Im Rahmen des Calls werden die jüngste FDA 510(k)-Zulassung für das Monogram mBôs TKA System sowie die Genehmigung zur Einleitung klinischer Studien in Indien besprochen. Vor dem Call wird eine ausführliche Pressemitteilung veröffentlicht, und eine Präsentation wird über die Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
AUSTIN, TX / ACCESS Newswire / May 6, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, will hold a conference call webcast on Wednesday, May 14, 2025 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the first quarter ended March 31, 2025, and to discuss regulatory updates, including its recent FDA 510(k) Clearance for the Monogram mBôsTM TKA System and approval to start clinical trials in India, and key milestones. A press release detailing these results will be issued prior to the call.
Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call webcast, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company's website here.
To access the call, please use the following information:
Date: | Wednesday, May 14, 2025 |
Time: | 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) |
Registration Link: |
The conference call webcast will be broadcast live and available for replay at the investor relations section of the Company's website here.
About Monogram Technologies Inc.
Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.
Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced, better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored.
Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances.
The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation.
To learn more, visit www.monogramtechnologies.com.
Investor Relations
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
MGRM@mzgroup.us
SOURCE: Monogram Technologies Inc.
View the original press release on ACCESS Newswire
FAQ
When is Monogram Technologies (MGRM) Q1 2025 earnings call?
What will be discussed in MGRM's Q1 2025 earnings call?
Who will host Monogram Technologies' Q1 2025 earnings call?
What recent regulatory approvals has MGRM received?
